- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04093531
Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome
July 6, 2022 updated by: Ummara Shah, University of Rochester
This pilot study will make a preliminary determination of the safety of ustekinumab in patients with Primary Sjogren's Syndrome (PSS) and assess the response of systemic measures of inflammation (biomarkers).
Study Overview
Detailed Description
This is a single-center, open label, pilot trial of ustekinumab in patients with Primary Sjögren's Syndrome (PSS).
Up to 15 subjects will receive an infusion loading dose of 6 mg/kg of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and week 20.
Subjects will be followed for 24 weeks.
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
A subject who has met all of the following criteria is eligible for participation in the study:
- Has provided written informed consent
- Between the ages of 18-75 years (inclusive)
- Body weight ≥ 40 kg
Meets the 2016 ACR EULAR criteria (score >4)
- 3 points- Labial salivary gland with focal lymphocytic sialadenitis and focus score of >1 foci/4 mm2‡
- 3 Points- Anti-SSA/Ro positive
- 1 Point- Ocular Staining Score >5 in at least 1 eye
- 1 Point- Schirmer's test <5 mm/5 minutes in at least 1 eye
- 1 Point- Unstimulated whole saliva flow rate <0.1 ml/minute
- If taking prednisone (or equivalent corticosteroid), the dose must be ≤ 10 mg/day and stable for at least 4 weeks prior to baseline visit
- If taking hydroxychloroquine, the dose must be stable for at least 12 weeks prior to baseline.
- If taking a cholinergic stimulant (e.g. pilocarpine, cevimeline), the dose must be stable for at least 4 weeks prior to baseline.
- If a male of reproductive potential, must agree to practice two highly effective forms of contraception during the study (one of which must be a barrier method) and be able to continue contraception for 20 weeks after his last dose of study agent Subject must also agree not to donate sperm up to 20 weeks after his last dose of study agent.
- If a female of childbearing potential, must agree to practice two highly effective forms of contraception during the study (one of which must be a barrier method) and able to continue contraception for 20 weeks after her last dose of study agent.
A subject who meets any of the following criteria is disqualified from participation in the study:
- Has a chronic or persistent infection that might be worsened by immunosuppressive treatment (e.g., HIV, hepatitis B, hepatitis C, or tuberculosis).
- History of untreated TB or positive QuantiFERON TB-Gold during screening period. If a subject has previously received an adequate course of therapy for either latent (9 months of isoniazid in a locale where rates of primary multi-drug resistant TB infection are <5%) or active TB infection, a QuantiFERON TB-Gold test need not be obtained, but a chest radiograph or other appropriate image must still be obtained if not done so within the prior 3 months.
- History of recurrent significant infections or occurrence of a serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within twelve weeks prior to Day 0.
- Active symptomatic infection within two weeks prior to Day 0.
- Receipt of live vaccine within four weeks prior to Day 0.
- History or presence of primary or secondary immunodeficiency.
- History of any life-threatening allergic reactions to pilocarpine or any components of ustekinumab. Pilocarpine will be used to stimulate salivary flow in order to assess flow rate.
- Is currently pregnant or nursing.
- Concurrent use of anticholinergic agents, such as tricyclic antidepressants, antihistamines, phenothiazines, antiparkinsonian drugs, anti-asthmatic medications, or gastrointestinal (GI) medications that cause xerostomia in more than 10% of patients.
Treatment with any of the following within the defined period prior to the screening and Day 0 visits:
- 12 months for rituximab
- 24 weeks for cyclophosphamide
- 8 weeks for azathioprine, cyclosporine, methotrexate, and mycophenolate mofetil
- 4 weeks for intravenous immunoglobulin
- 4 weeks for etanercept
- 8 weeks for adalimumab
- 12 weeks for infliximab
- 8 weeks Golimumab
- 8weeks Certolizumab pegol
- 16 weeks Abatacept
- 4 weeks Tocilizumab SQ
- 16 weeks Tocilizumab IV
- 4 weeks Tofacitinib and Tofacitinib XR
- Prednisone (or equivalent corticosteroid) > 10 mg/day.
- A definite diagnosis of RA, SLE, systemic sclerosis, or dermatomyositis.
- A history of alcohol or substance abuse.
- A history of head and neck radiation therapy, sarcoidosis, or graft-versus-host disease.
- A history of malignancy, except for a resected basal or major squamous cell carcinoma, cervical dysplasia, or in situ cervical cancer Grade I, within the last five years.
Abnormal laboratory results for the following parameters at the baseline visit:
- Absolute neutrophil count (ANC): < 1500/mm3
- Platelets: < 100,000/mm3
- Hemoglobin: < 9 grams (g)/deciliter (dL)
- Serum creatinine: ≥ 2.0 mg/dL
- AST: > 1.5x upper limit of normal
- ALT: > 1.5x upper limit of normal.
- A psychiatric disorder rendering the subject incapable of providing informed consent.
- Plans for foreign travel to countries other than Canada or Western Europe within the treatment period.
- Inability or unwillingness to follow the protocol
- Any condition or treatment that, in the opinion of the investigator, places the subject at an unacceptable risk as a participant in the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ustekinumab
All subjects will receive an intravenous loading dose of 6 mg/kg at their baseline visit.
650mg acetaminophen and 60mg allegra will be given as premedication to the infusion.
All patients will receive 90mg ustekinumab by a subcutaneous injection at all subsequent dosing visits.
Subcutaneous injections do not require any premedication.
Drug will be administered by qualified personnel.
|
Up to 15 subjects will receive an infusion loading dose of 6 mg/kg of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and week 20.
Subjects will be followed for 24 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in The European League Against Rheumatism (EULAR) Sjogren's Syndrome Patient Reported Index (ESSPRI) score from Baseline to Week 24
Time Frame: 24 weeks
|
The primary endpoint is a well-established, patient reported questionnaire for use in PSS, the ESSPRI.
The ESSPRI is composed of 3 scales - dryness, fatigue, and pain.
Each scale is measured 0 - 10, 0 being no symptoms, 10 being maximal imaginable dryness, fatigue or pain.
The total score is the mean score of the three scales.
Baseline ESSPRI total score will be compared to week 24, end of treatment, ESSPRI total score.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Short Form Health Survey (SF-36) Patient Reported Outcome Measure between day 0 and week 24
Time Frame: 24 weeks
|
The SF-36 is a measure of health-related quality-of-life.
It's a 36-item patient-reported questionnaire that covers 8 health domains.
Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state.
Changes in total scores in each domain from BL to week 24 will be measured.
|
24 weeks
|
Change in serum biomarkers of inflammation from baseline to week 24
Time Frame: 24 weeks
|
To determine whether the standard dosing schedule for ustekinumab lowers serum biomarkers of inflammation in patients with PSS blood will be collected at baseline, week 12 and week 24 for the following mechanistic studies: Serum levels of TNFα, IL-6, IL17, IL17A, IL17F, IL22, IL12, IL23, BAFF, B and T cell, blood interferon signature.
Means, medians, standard deviations, minimums and maximums will be computed for each continuous mechanistic endpoint.
|
24 weeks
|
Number of participants with treatment-emergent adverse events as defined by ICH definition of AE.
Time Frame: 24 weeks
|
Safety of ustekinumab in PSS patients will be measured by incidence of serious and non-serious adverse events per ICH definitions from prior to treatment and after the first dose of study drug.
Number of events and number (%) of participants experiencing events will be summarized by system organ class and preferred term for each.
In addition, AEs will be summarized by maximum severity and relationship to study drug.
|
24 weeks
|
Change in total score of the EULAR Sjogren's syndrome disease activity index (ESSDAI) from baseline to week 24.
Time Frame: 24 weeks.
|
The ESSDAI is a disease activity measurement that has 12 domains.
The score of each domain is the product of the weight of the domain by the level of activity.
Activity levels are 0 - 3, 0 being no activity, 3 being high activity.
The total score is the sum of the score of all domains.
Change in total score from BL to week 24 will be measured.
|
24 weeks.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ummara Shah, MD, Assistant Professor of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 15, 2020
Primary Completion (Actual)
May 11, 2022
Study Completion (Actual)
May 11, 2022
Study Registration Dates
First Submitted
August 5, 2019
First Submitted That Met QC Criteria
September 16, 2019
First Posted (Actual)
September 18, 2019
Study Record Updates
Last Update Posted (Actual)
July 8, 2022
Last Update Submitted That Met QC Criteria
July 6, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Eye Diseases
- Disease
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Stomatognathic Diseases
- Mouth Diseases
- Lacrimal Apparatus Diseases
- Arthritis, Rheumatoid
- Xerostomia
- Salivary Gland Diseases
- Dry Eye Syndromes
- Syndrome
- Sjogren's Syndrome
- Dermatologic Agents
- Ustekinumab
Other Study ID Numbers
- Ustekinumab for PSS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Sjögren Syndrome
-
Galapagos NVTerminatedPrimary Sjögren SyndromeGermany, Greece, Poland, Hungary, Ukraine
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Recruiting
-
University of CopenhagenRigshospitalet, Denmark; ITI Foundation; GigtforeningenCompletedDental Implant | Primary Sjögren Syndrome
-
University Hospital, LimogesCompleted
-
Akdeniz UniversityCompleted
-
Rise Therapeutics LLCNot yet recruitingSjogren's Syndrome | Sjögren | Sjögren Syndrome, Unspecified
-
Ankara Education and Research HospitalCompletedPrimary Sjögren SyndromeTurkey
-
University Hospital, BrestUnknownPrimary Sjögren Syndrome
-
Federal University of São PauloCompletedPrimary Sjögren Syndrome
-
University Hospital, BrestUnknown
Clinical Trials on Ustekinumab
-
Janssen Research & Development, LLCCompletedPsoriasisUnited States, Germany, Taiwan, Belgium, Korea, Republic of, Canada, Poland, Hungary, Netherlands
-
Janssen Research & Development, LLCCompletedPrimary Biliary CirrhosisUnited States, Canada
-
Centocor, Inc.CompletedCrohn's DiseaseUnited States, France, United Kingdom, Germany, Spain, Belgium, Israel, Australia, Canada, Netherlands, New Zealand, Austria
-
Samsung Bioepis Co., Ltd.CompletedPsoriasis | Moderate to Severe Plaque PsoriasisCzechia, Estonia, Hungary, Korea, Republic of, Latvia, Lithuania, Poland, Ukraine
-
Jewish General HospitalCompletedType 1 Diabetes MellitusCanada
-
Janssen Research & Development, LLCCompletedPsoriasisFrance, Ukraine, United Kingdom, Germany, Portugal, Canada, Belgium, Russian Federation, Hungary, Sweden
-
Bioeq GmbHCompletedPlaque PsoriasisPoland, Estonia, Ukraine, Georgia
-
Centocor, Inc.Completed
-
Janssen Research & Development, LLCTerminatedLupus Erythematosus, SystemicUnited States, Japan, Korea, Republic of, Canada, Taiwan, Thailand, Germany, China, Serbia, Spain, Portugal, Russian Federation, Poland, Ukraine, Lithuania, South Africa, Hungary, Argentina, Bulgaria, Colombia
-
Janssen Research & Development, LLCWithdrawnLupus Erythematosus, SystemicChina